Skip to main content

Advertisement

Log in

Empfehlung zum Einsatz kardialer Biomarker in der ESC-Leitlinie für perioperatives Management von Patient:innen bei nicht-kardiochirurgischen Operationen: Herausforderungen und Chancen

Recommendation on the use of cardiac biomarkers in the ESC guidelines for the perioperative management of patients undergoing non-cardiac surgery: challenges and opportunities

  • Gefäßmedizinische Evidenz
  • Published:
Gefässchirurgie Aims and scope Submit manuscript

Zusammenfassung

Der perioperative Myokardschaden (PMI) ist eine häufige Komplikation nach nicht-kardiochirurgischen Operationen und assoziiert mit einer hohen postoperativen Mortalität. Die aktuellen ESC-Leitlinien für perioperatives Management von Patient:innen bei nicht-kardiochirurgischen Operationen empfehlen ein routinemäßiges Troponinmonitoring vor nicht-kardiochirurgischen Operationen mit mittlerem und hohem Risiko bei Patient:innen mit erhöhtem Risiko für perioperative kardiovaskuläre Ereignisse, um einen PMI zu detektieren. Eine präoperative Troponinmessung wird empfohlen, um von einer chronischen Myokardschädigung als Ursache der Troponinerhöhung zu unterscheiden. Da die postoperative Mortalität von Patient:innen mit und ohne zusätzliche ischämieverdächtige Symptome oder EKG-Veränderungen signifikant erhöht ist, wird die Diagnose PMI alleinig anhand der Troponindynamik (z. B. hochsensitiver Troponin-T-Assay: Anstieg ≥ 14 ng/L) gestellt (im Vergleich zur Diagnose eines akuten Myokardinfarkts). Die Ursachen eines PMI sind heterogen und Patient:innen mit PMI benötigen eine systematische Abklärung sowie eine, an die genaue Ursache angepasste, Behandlung. Ein interdisziplinärer Ansatz ist wichtig für die erfolgreiche Implementation eines PMI-Screenings.

Abstract

Perioperative myocardial injury (PMI) is a common complication after non-cardiac surgery and is associated with high postoperative mortality. The current ESC guidelines on the perioperative management of patients undergoing non-cardiac surgery recommend routine perioperative troponin surveillance before medium- and high-risk non-cardiac surgery in patients at an increased risk for perioperative cardiovascular events in order to detect PMI. Measurement of preoperative troponin levels is recommended to differentiate from chronic myocardial injury as the cause of the increase in troponin. As postoperative mortality is significantly elevated in patients with and without additional ischemic symptoms or ECG changes, the diagnosis of PMI is solely based on troponin levels (e.g., high-sensitivity troponin T assay: increase ≥ 14 ng/L), as opposed to the diagnosis of acute myocardial infarction. The causes of PMI are heterogeneous and patients with PMI need a systematic work-up and treatment according to the precise cause. An interdisciplinary approach is mandatory for the successful implementation of PMI screening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E et al (2022) 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 43(39):3826–3924

    Article  PubMed  Google Scholar 

  2. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study I, Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A et al (2019) Association between complications and death within 30 days after noncardiac surgery. Cmaj 191(30):E830–E7

    Article  Google Scholar 

  3. Norderud K, Egholm G, Thim T, Olesen KKW, Madsen M, Jensen LO et al (2019) Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. Eur Heart J Qual Care Clin Outcomes 5(1):22–27

    Article  PubMed  Google Scholar 

  4. Duceppe E, Patel A, Chan MTV, Berwanger O, Ackland G, Kavsak PA et al (2020) Preoperative N‑terminal pro-B-type Natriuretic peptide and cardiovascular events after Noncardiac surgery: a cohort study. Ann Intern Med 172(2):96–104

    Article  PubMed  Google Scholar 

  5. Puelacher C, Lurati BG, Seeberger D, Sazgary L, Marbot S, Lampart A et al (2018) Perioperative myocardial injury after Noncardiac surgery: incidence, mortality, and characterization. Circulation 137(12:1221–1232

    Article  Google Scholar 

  6. Vestergaard KR, Jespersen CB, Arnadottir A, Soletormos G, Schou M, Steffensen R et al (2016) Prevalence and significance of troponin elevations in patients without acute coronary disease. Int J Cardiol 222:819–825

    Article  PubMed  Google Scholar 

  7. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al (2018) Fourth universal definition of myocardial infarction (2018). Circulation 138(20):e618–e51

    Article  PubMed  Google Scholar 

  8. Puelacher C, Bollen PB, Mills NL, Duceppe E, Popova E, Duma A et al (2021) Expert consensus on peri-operative myocardial injury screening in noncardiac surgery: A literature review. Eur J Anaesthesiol 38(6:600–608

    Article  Google Scholar 

  9. Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, Srinathan S et al (2014) Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 120(3):564–578

    Article  PubMed  Google Scholar 

  10. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S et al (2012) How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 33(18):2252–2257

    Article  CAS  PubMed  Google Scholar 

  11. Aakre KM, Saenger AK, Body R, Collinson P, Hammarsten O, Jaffe AS et al (2022) Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC committee on clinical application of cardiac bio-markers. Clin Chem 68(8):1022–1030

    Article  PubMed  Google Scholar 

  12. Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI et al (2017) Relationship between Intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after Noncardiac surgery: a retrospective cohort analysis. Anesthesiology 126(1:47–65

    Article  Google Scholar 

  13. Turan A, Rivas E, Devereaux PJ, Bravo M, Mao G, Cohen B et al (2021) Association between postoperative haemoglobin concentrations and composite of non-fatal myocardial infarction and all-cause mortality in noncardiac surgical patients: post hoc analysis of the POISE-2 trial. Br J Anaesth 126(1):87–93

    Article  CAS  PubMed  Google Scholar 

  14. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter‑2 inhibitors: a systematic review. Br J Anaesth 123(1):27–36

    Article  CAS  PubMed  Google Scholar 

  15. Group PS, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K et al (2008) Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 371(9627):1839–1847

    Article  Google Scholar 

  16. Toda H, Nakamura K, Shimizu K, Ejiri K, Iwano T, Miyoshi T et al (2020) Effects of Bisoprolol Transdermal patches for prevention of Perioperative myocardial injury in high-risk patients undergoing non-cardiac surgery—multicenter randomized controlled study. Circ J 84(4):642–649

    Article  CAS  PubMed  Google Scholar 

  17. Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC et al (2012) Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 307(21):2295–2304

    Article  CAS  PubMed  Google Scholar 

  18. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA et al (2018) The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg 67(1):2–77.e2

    Article  PubMed  Google Scholar 

  19. Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, European Society for Vascular Surgery (ESVS) et al (2022) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Acta Angiol 28(3):69–146

    Google Scholar 

  20. Caruana BC, Jackson SM, Ngyuen Khuong J, Campbell R, Liu Z, Ramson DM et al (2020) Systematic review and meta-analysis of postoperative troponin as a predictor of mortality and major adverse cardiac events after vascular surgery. J Vasc Surg 72(3):1132–1143.e1

    Article  Google Scholar 

  21. Mattisson L, Bojan A, Enocson A (2018) Epidemiology, treatment and mortality of trochanteric and subtrochanteric hip fractures: data from the Swedish fracture register. BMC Musculoskelet Disord 19(1):369

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chew MS, Saugel B, Lurati-Buse G (2023) Perioperative troponin surveillance in major noncardiac surgery: a narrative review. Br J Anaesth 130(1):21–28

    Article  PubMed  Google Scholar 

  23. Thomas KN, Cotter JD, Williams MJ, van Rij AM (2016) Diagnosis, incidence, and clinical implications of perioperative myocardial injury in vascular surgery. Vasc Endovascular Surg 50(4):247–255

    Article  PubMed  Google Scholar 

  24. van Waes JA, Grobben RB, Nathoe HM, Kemperman H, de Borst GJ, Peelen LM et al (2016) One-year mortality, causes of death, and cardiac interventions in patients with postoperative myocardial injury. Anesth Analg 123(1):29–37

    Article  PubMed  Google Scholar 

  25. Popova E, Alonso-Coello P, Álvarez-García J, Paniagua-Iglesias P, Rué-Monné M, Vives-Borrás M et al (2023) Cost-effectiveness of a high-sensitivity cardiac troponin T systematic screening strategy compared with usual care to identify patients with peri-operative myocardial injury after major noncardiac surgery. Eur J Anaesthesiol 40(3):179–189

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Petra Hillinger.

Ethics declarations

Interessenkonflikt

P. Hillinger: Honorar für Vorträge von Roche Diagnostics. J. Falkensammer: Honorare für Vorträge und/oder Beraterfunktionen von Terumo Aortic, Roche Diagnostics. B. Gustorff: Beraterhonorar von Roche Diagnostics. J. Knotzer: Honorar für Vorträge von AOP Pharma, Sintetica, Orion Pharma, Medtronics, Roche. K. Huber: Honorar für Vorträge und Konsultationen für AMGEN, AstraZeneca, Bayer, Böhringer-Ingelheim, BMS, Chiesi, Daiichi Sankyo, Eli Lilly, Novartis, NovoNordisk und Sanofi Aventis. A. Duma: Honorar für Vorträge von Roche Diagnostics. M. Muthspiel, H. Alber, M. Frossard, J. Holfeld und B. Kabon geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Dieser Beitrag erschien zuerst in Journal für Kardiologie – Austrian Journal of Cardiology (2023) 30(5-6):132–137.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muthspiel, M., Hillinger, P., Alber, H. et al. Empfehlung zum Einsatz kardialer Biomarker in der ESC-Leitlinie für perioperatives Management von Patient:innen bei nicht-kardiochirurgischen Operationen: Herausforderungen und Chancen. Gefässchirurgie 28, 520–526 (2023). https://doi.org/10.1007/s00772-023-01023-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00772-023-01023-2

Schlüsselwörter

Keywords

Navigation